SMTI

Sanara Medtech Inc

Add to Watchlist

Advanced Chart

35.100

+0.730(+2.120%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

35.000

Open

35.000

VWAP

34.96

Vol

23.61K

Mkt Cap

311.35M

Low

34.850

Amount

825.55K

EV/EBITDA(TTM)

Total Shares

8.63M

301.85M

EV/OCF(TTM)

P/S(TTM)

3.17

Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

25.78M

+18.93%

25.18M

+24.88%

23.48M

+26.64%

Estimates Revision

The market is revising Upward the revenue expectations for Sanara MedTech Inc. (SMTI) for FY2025, with the revenue forecasts being adjusted by 2.04% over the past three months. During the same period, the stock price has changed by -0.43%.

Revenue Estimates for FY2025

Revise Upward

+2.04%

In Past 3 Month

Stock Price

Go Down

-0.43%

In Past 3 Month

2 Analyst Rating

38.18% Upside

Wall Street analysts forecast SMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMTI is 48.50 USD with a low forecast of 46.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

38.18% Upside

Current: 35.100

Low

46.00

Averages

48.50

High

51.00

38.18% Upside

Current: 35.100

Low

46.00

Averages

48.50

High

51.00

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$50 → $51

2025-03-26

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$50 → $51

2025-03-26

Maintains

Strong Buy

Reason

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

$46

2025-03-26

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

$46

2025-03-26

Reiterates

Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$50

2025-01-23

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$50

2025-01-23

Reiterates

Strong Buy

Reason

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

$44

2025-01-23

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

$44

2025-01-23

Reiterates

Buy

Reason

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

$44

2025-01-22

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

$44

2025-01-22

Reiterates

Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Initiates

$50

2024-12-23

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$50

2024-12-23

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Sanara Medtech Inc (SMTI.O) is -18.23, compared to its 5-year average forward P/E of -8.64. For a more detailed relative valuation and DCF analysis to assess Sanara Medtech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.64

Current PE

-18.23

Overvalued PE

66.26

Undervalued PE

-83.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.22

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

17.40

Undervalued EV/EBITDA

-10.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.40

Current PS

2.74

Overvalued PS

7.19

Undervalued PS

1.60

Financials

Annual

Quarterly

FY2024Q4

YoY :

+48.70%

26.31M

Total Revenue

FY2024Q4

YoY :

-38.03%

-1.35M

Operating Profit

FY2024Q4

YoY :

+547.99%

-1.70M

Net Income after Tax

FY2024Q4

YoY :

+500.00%

-0.18

EPS - Diluted

FY2024Q4

YoY :

-192.65%

836.42K

Free Cash Flow

FY2024Q4

YoY :

+4.25%

87.26

Gross Profit Margin - %

FY2024Q4

YoY :

-94.63%

-0.29

FCF Margin - %

FY2024Q4

YoY :

+336.49%

-6.46

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SMTI News & Events

Events Timeline

2025-03-25 (ET)

2025-03-25

07:01:36

Sanara MedTech reports Q4 EPS (18c) vs (3c) last year

2025-01-24 (ET)

2025-01-24

06:04:56

Biomimetic Innovations executes license, distribution agreement with Sanara

2025-01-21 (ET)

2025-01-21

15:13:48

Sanara MedTech enters exclusive license agreement with, investment in Biomimetic

News

6.5

03-26Benzinga

Where Sanara MedTech Stands With Analysts

4.0

03-26Benzinga

Cantor Fitzgerald Reiterates Overweight on Sanara MedTech, Maintains $46 Price Target

9.5

03-25Newsfilter

Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited)

People Also Watch

Princeton Bancorp Inc

Reitar Logtech Holdings Ltd

Chemung Financial Corp

FAQ

What is Sanara Medtech Inc (SMTI) stock price today?

The current price of SMTI is 35.1 USD — it has increased 2.12 % in the last trading day.

SMTI

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

SMTI News & Events

Events Timeline

News

People Also Watch

FAQ

What is Sanara Medtech Inc (SMTI) stock price today?

What is Sanara Medtech Inc (SMTI)'s business?

What is the price predicton of SMTI Stock?

What is Sanara Medtech Inc (SMTI)'s revenue for the last quarter?

What is Sanara Medtech Inc (SMTI)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Sanara Medtech Inc (SMTI)'s fundamentals?

How many employees does Sanara Medtech Inc (SMTI). have?

What is Sanara Medtech Inc (SMTI) market cap?